Document is current
Any future updates will be listed below
-
Authors
Cardwell, Chris R. https://orcid.org/0000-0002-2689-4335
Baxter, Sarah M. https://orcid.org/0000-0002-5762-0396
Snelling, Andrew JHL https://orcid.org/0000-0002-2882-2079
Chen, Daniel Tzu-Hsuan https://orcid.org/0000-0001-9849-4966
Atakpa, Emma C.
McMenamin, Úna
McIntosh, Stuart A. https://orcid.org/0000-0002-4123-9611
Hicks, Blánaid
Coupland, Carol AC
Brady, Aaron J.
Bannon, Finian J.
Hippisley-Cox, Julia
-
Funding
Funding for this research was provided by:
Cancer Research UK (PRCPJT-Nov22/100017)
- License Information
-
More Information
Article History
Received: 5 June 2023
Accepted: 9 December 2025
First Online: 21 December 2025
Competing interests
: S.A.Mc.I. reports institutional funding for honoraria from Roche, MSD and AstraZeneca, for advisory boards from Roche, Lily and MSD, for talks from Roche and MSD, and research funding from Novartis. S.A.Mc.I. also reports personal funding for talks from B.D. Bard and conference travel and support from Roche and Lilly. A.J.B. reports institutional funding from Pfizer, MSD and Shionogi to support delivery of educational events. The remaining authors declare they have no relevant financial or non-financial interests.
